Rationale and design of the magnesium in coronaries (MAGIC) study: A clinical trial to reevaluate the efficacy of early administration of magnesium in acute myocardial infarction.

What Was Tested

The paper reports a study of Magnesium Sulfate, published as a randomized controlled trial.

Mortality rate from ST-elevation myocardial infarction remains high in elderly patients and in patients who are not eligible for reperfusion therapy.

Who Took Part

By PubMed's age tags, the people studied were older adults.

Magnesium in Coronaries (MAGIC) is a large, simple trial designed to maximize the potential treatment effect of magnesium. 10, 400 high-risk patients with ST-elevation myocardial infarction will be randomly assigned to early treatment with intravenous magnesium sulfate or matching placebo.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Magnesium Sulfate and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Magnesium Sulfate, so expectations could not easily colour the readings.

Some participants received a placebo instead of Magnesium Sulfate, giving a reference point.

What Was Measured

The subject headings attached to it are Calcium Channel Blockers, Electrocardiography, Magnesium Sulfate, Myocardial Infarction and Survival Rate.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Magnesium Sulfate.

Results are reported in around 1 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2000 (American heart journal), a journal based in United States.

More context: all human trials.